(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 December 2010 (23.12.2010)

PCT

(10) International Publication Number
WO 2010/148223 A3

(51) International Patent Classification:
C07K 16/22 (2006.01) *C12N 15/63* (2006.01)
A61P 35/00 (2006.01) *A61K 47/48* (2006.01)
A61K 39/395 (2006.01) *A61P 37/00* (2006.01)
C12N 15/13 (2006.01)

(21) International Application Number:
PCT/US2010/039029

(22) International Filing Date:
17 June 2010 (17.06.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/218,005 17 June 2009 (17.06.2009) US

(71) Applicant *(for all designated States except US)*: **ABBOTT BIOTHERAPEUTICS CORP.** [US/US]; 1500 Seaport Blvd., Redwood City, CA 94063 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **HARDING, Fiona** [US/US]; 772 Lewis Street, Santa Clara, CA 95050 (US). **AKAMATSU, Yoshiko** [US/US]; 514 Driscoll Place, Palo Alto, CA 94306 (US). **DUBRIDGE, Robert, B.** [US/US]; 825 Holly Road, Belmont, CA 94002 (US). **POWERS, David, B.** [US/US]; 77 Live Oak Avenue, Fairfax, CA 94930 (US).

(74) Agents: **ABU-SHAAR, Muna** et al.; Dechert LLP, P.O. Box 390460, Mountain View, CA 94039 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: ANTI-VEGF ANTIBODIES AND THEIR USES

Antibody Chain	CDR No.	Residue	Position in CDR	Kabat No.
Light	1	S	1	24
		A	2	25
		S	3	26
		Q	4	27
		D	5	28
		I	6	29
		S	7	30
		N	8	31
		Y	9	32
		L	10	33
		N	11	34
Light	2	F	1	50
		T	2	51
		S	3	52
		S	4	53
		L	5	54
		H	6	55
		S	7	56
Light	3	Q	1	89
		Q	2	90
		Y	3	91
		S	4	92
		T	5	93
		V	6	94
		P	7	95
		W	8	96
		T	9	97

TABLE 2

(57) Abstract: The present disclosure relates to antibodies directed to vascular endothelial growth factor ("VEGF") and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of VEGF.

WO 2010/148223 A3

WO 2010/148223 A3

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
3 March 2011